ZENTALIS PHARMACEUTICALS INC (ZNTL) — insider trading
Health Care · NASDAQ
ZENTALIS PHARMACEUTICALS INC (ZNTL) has 18 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase and 9 open-market sales among the most recent 18 (latest 2026-09-30).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Bruns Ingmar | Officer (Chief Medical Officer) | Grant / award / vesting | 9,727 | $2.18 | $21.2K | Form 4 |
| 2026-08-14 | WALTERS GROUP; WALTERS WILLIAM THURMAN; WALTERS SUSAN BERKLEY | 10% owner | Open-market purchase | 4,335,000 | $3.50 | $15.17M | Form 4 |
| 2026-06-16 | Myers Scott Dunseth | Director | Grant / award / vesting | 57,100 | — | $0 | Form 4 |
| 2026-06-16 | Kariuki Enoch | Director | Grant / award / vesting | 57,100 | — | $0 | Form 4 |
| 2026-06-16 | Walker Luke Nathaniel | Director | Grant / award / vesting | 57,100 | — | $0 | Form 4 |
| 2026-06-16 | Skvarka Jan | Director | Grant / award / vesting | 57,100 | — | $0 | Form 4 |
| 2026-06-16 | Johnson David Michael | Director | Grant / award / vesting | 57,100 | — | $0 | Form 4 |
| 2026-05-26 | Campbell Shannon | Director | Grant / award / vesting | 114,200 | — | $0 | Form 4 |
| 2026-02-10 | Vultaggio Vincent | Officer (PAO and PFO) | Open-market sale | 6,894 | $2.42 | $16.7K | Form 4 |
| 2026-02-09 | EASTLAND JULIA MARIE | Director, Officer (CEO & President) | Open-market sale | 889 | $2.39 | $2.1K | Form 4 |
| 2026-02-09 | Vultaggio Vincent | Officer (PAO and PFO) | Open-market sale | 3,379 | $2.39 | $8.1K | Form 4 |
| 2026-02-09 | Bruns Ingmar | Officer (Chief Medical Officer) | Open-market sale | 335 | $2.39 | $802 | Form 4 |
| 2026-02-06 | EASTLAND JULIA MARIE | Director, Officer (CEO & President) | Open-market sale | 7,866 | $2.43 | $19.1K | Form 4 |
| 2026-02-06 | Vultaggio Vincent | Officer (PAO and PFO) | Open-market sale | 29,951 | $2.43 | $72.8K | Form 4 |
| 2026-02-06 | Bruns Ingmar | Officer (Chief Medical Officer) | Open-market sale | 2,962 | $2.43 | $7.2K | Form 4 |
| 2026-02-03 | Vultaggio Vincent | Officer (PAO and PFO) | Open-market sale | 556 | $2.52 | $1.4K | Form 4 |
| 2026-02-02 | Vultaggio Vincent | Officer (PAO and PFO) | Open-market sale | 2,540 | $2.55 | $6.5K | Form 4 |
| 2026-01-08 | Vultaggio Vincent | Officer (PAO and PFO) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
Ask the chat about ZNTL's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ZENTALIS PHARMACEUTICALS INC (ZNTL).
Last updated 2026-09-30 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.